Shandong Weigao Blood Purification Products603014.SHValuation Analysis

As of Oct 19, 2026, Shandong Weigao Blood Purification Products (603014.SH) trades at a P/E of 41.10x, P/B of 2.80x, P/S of 5.74x, and a dividend yield of 1.07%.
Longitudinal percentile comparison: P/E sits at the 93rd percentile over the trailing 10Y window (vs. 93rd percentile over 3Y); P/B sits at the 93rd percentile over the trailing 10Y window (vs. 93rd percentile over 3Y); P/S sits at the 93rd percentile over the trailing 10Y window (vs. 93rd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 55th percentile within its industry and the 54th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.07%, ranking at the 47th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 0.0 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Shandong Weigao Blood Purification Products operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.